top of page

Dabrafenib

Anti-neoplastic

MECHANISM OF ACTION

TKI; Inhibits BRAF, inhibiting tumor growth.

MECHANISM OF KIDNEY INJURY

AIN reported and glomerular sclerosis

CLINICAL KIDNEY SYNDROME

Unclear but causes cardiomyopathy , QT prolongation, skin rashes, and VTE

CARDIOVASCULAR ADVERSE EFFECTS

n/a

LYTE ABNORMALITIES

RISK FACTORS

MITIGATION STRATEGIES

SUGGESTIONS 

NOTES/COMMENTS

eGFR < 60 ml/min, no dose adjustment

PHARMACOKINETICS

Molecular Weight

519

Volume of Distribution

70.3 L

Plasma Protein Binding

99%

Metabolism

Bioavailability

Half-life elimination

8 hours

Time to peak

Excretion

Feces 71% Urine 23%

Dialyzable?

REF:

PMID: 35029901

PATHOLOGY SLIDES:

ENTRY UPDATES:

Raad Chowdhury

United States

Sep 25, 2022

bottom of page